Bioretina

Bioretina is a Turkish biotechnology and medical device company specializing in the treatment of rare and degenerative retinal and optic nerve diseases. Headquartered at Ankara University Technopolis, the company has developed the Magnovision technology, a non-invasive device that uses high-frequency repetitive electromagnetic stimulation (rEMS) to enhance retinal function and facilitate the delivery of therapeutic agents. Bioretina's clinical pipeline focuses on combining Magnovision with regenerative therapies, such as Wharton's Jelly-derived Mesenchymal Stem Cells (WJ-MSC) and Platelet-Rich Plasma (PRP), to treat conditions like Retinitis Pigmentosa and Toxic Optic Neuropathy. Their research has demonstrated significant potential in slowing disease progression and improving visual outcomes for patients with previously untreatable hereditary retinal dystrophies.